On 28 October 2015, with Huang Yaping, Du En and Li Shasha as legal counsel, Wuhan Changlian Laifu Pharmaceutical Co., Ltd. (stock code: 834239; stock short name: Changlian Laifu) was listed on National Equities Exchange and Quotations.
Changlian Laifu is a hi-tech pharmaceutical company focuses on the R&D, production and marketing of Medicament for the treatment of cardiocerebral and vascular disease, infection,diabetes,respiratory system and digestive system disease. The main products are about 40 different kinds and specifications which are Sodium Aescinate for Injection, Aciclovir for Injection, Potassium Sodium Dehydroandroan drographolide Succinate for Injection, Thioctic Acid for Injection, Ornidazole for Injection, Thrombin etc.